TriSalus Life Sciences, Inc. Cash and Restricted Cash
TriSalus Life Sciences, Inc. (TLSI) had Cash and Restricted Cash of $46.29 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $46.29M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $56.55M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $20.79M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $23.04M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $46.29M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $56.55M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $20.79M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $23.04M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $26.84M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $13.35M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $8.88M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $11.64M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $16.83M 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $4.32M 10-Q · filed 2025-05-15 | |
| 2023-12-31 | $12.13M 10-K · filed 2026-03-05 | |
| 2023-09-30 | $21.63M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $4.15M 10-Q · filed 2024-08-14 | $103.97K 10-Q · filed 2023-08-02 |
| 2023-03-31 | $7.02M 10-Q · filed 2024-05-15 | $136.80K 10-Q · filed 2023-05-12 |
| 2022-12-31 | $9.66M 10-K/A · filed 2025-05-30 | $153.56K 10-K · filed 2023-03-22 |
| 2022-09-30 | $12.34M 10-Q · filed 2023-11-14 | $207.60K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $69.18K 10-Q · filed 2023-08-02 | |
| 2022-03-31 | $50.93K 10-Q · filed 2023-05-12 | |
| 2021-12-31 | $30.30M 10-K · filed 2024-04-11 | $200.88K 10-K · filed 2022-03-03 |
| 2021-09-30 | $277.81K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $642.94K 10-Q · filed 2022-08-10 | |
| 2021-03-31 | $1.13M 10-Q · filed 2022-05-11 | |
| 2020-12-31 | $1.33M 10-K · filed 2023-03-22 | |
| 2020-09-10 | $0.00 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |